Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioNexus Gene Lab's share price for the quarter that ended in Mar. 2026 was $2.1406. BioNexus Gene Lab's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2.42 Mil. Therefore, BioNexus Gene Lab's market cap for the quarter that ended in Mar. 2026 was $5.17 Mil.
BioNexus Gene Lab's quarterly market cap
declined
from Sep. 2025 ($9.83 Mil) to Dec. 2025 ($9.55 Mil) and
declined
from Dec. 2025 ($9.55 Mil) to Mar. 2026 ($5.17 Mil).
BioNexus Gene Lab's annual market cap
declined
from Dec. 2023 ($9.37 Mil) to Dec. 2024 ($5.03 Mil) but then
increased
from Dec. 2024 ($5.03 Mil) to Dec. 2025 ($9.55 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioNexus Gene Lab's Enterprise Value for Today is $0.31 Mil.
BioNexus Gene Lab (NAS:BGLC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioNexus Gene Lab Market Cap Related Terms
BioNexus Gene Lab Market Cap Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Market Cap vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Market Cap distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioNexus Gene Lab's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Market Cap of $4.06 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioNexus Gene Lab and its competitors. According to the industry distribution chart, BioNexus Gene Lab ranks #1552 out of 1632 companies in the Chemicals industry, placing it in the top 95.1%.
Is BioNexus Gene Lab's Market Cap too high?
BioNexus Gene Lab's current Market Cap is $4.06 Mil. The Chemicals industry median Market Cap is 291.67. BioNexus Gene Lab's value of $4.06 Mil is 98.6% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #1552 out of 1632 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Market Cap compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1552 out of 1632 companies for Market Cap. This places BioNexus Gene Lab in the lower half of its industry. The industry median Market Cap is 291.67. BioNexus Gene Lab's value of $4.06 Mil is 98.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Chemicals company?
The median Market Cap among Chemicals companies is 291.67, based on 1,632 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Market Cap of $4.06 Mil is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Market Cap is 291.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Market Cap is $4.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Market Cap is $4.06 Mil and 98.6% below the Chemicals industry median of 291.67. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Market Cap is $4.06 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Market Cap: $4.06 Mil
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
Industry Position: 98.6% below the Chemicals median (#1552 of 1632)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
